---
title: "Gland MRI Radiomics Predicts Time to Pathologic Progression on Prostate Cancer Active Surveillance"
id: "medrxiv-6-automated-gland-mri-radiomics-for-predicting-time-to-pathologic-progression"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-automated-gland-mri-radiomics-for-predicting-time-to-pathologic-progression"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1?rss=1"
published_at: "2026-11-19T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Gland MRI Radiomics Predicts Time to Pathologic Progression on Prostate Cancer Active Surveillance
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-automated-gland-mri-radiomics-for-predicting-time-to-pathologic-progression
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1?rss=1)
- **Published At:** 2026-11-19T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Retrospective, single-institution cohort of men with **prostate cancer** on active surveillance (grade group 1 or favorable grade group 2) who underwent fusion-targeted and systematic biopsy. - Development set and internal test set were assigned by site: 410 men for development, 112 for internal testing; median age 64 years (IQR 59–68). - Automated gland segmentation achieved a mean Dice of 0.89 ± 0.04 using **nnU-Net**; investigators used gland-level contours rather than manual lesion-only masks. - Radiomic features from gland segmentations were selected with LASSO-penalized survival regression; the chosen features were fed into an accelerated failure time model implemented with **XGBoost**. - Comparator models included clinicopathologic variables and lesion-based radiomics; model performance assessed via C-index, time-dependent AUC, Kaplan–Meier survival curves, and decision curve analysis. - The **gland radiomics** model produced a C-index of 0.77 versus 0.68 for both clinicopathologic and lesion radiomics models (adjusted P ≤ .017); highest time-dependent AUC was 0.87 at 36 months (95% CI: 0.78–0.94). - Risk stratification separated cohorts: 36-month progression-free survival 63.9% (high-risk) vs 100% (low-risk); 48-month PFS 55.4% vs 93.8% (log-rank P < .001). - At a 0.25 risk threshold, 49.1% and 31.3% were classified low risk at 36 and 48 months respectively; NPV reported as 1.00 and PPV as 0.36 at those thresholds. - Data are not publicly available due to privacy and institutional restrictions; de-identified data may be obtained from the corresponding author with IRB approval. The study is a preprint and has not undergone peer review.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=ithXVdpmZdcPJrB2EYfJUYVc2jk37L6exhC9VaQvARc-1795158954.122944-1.2.1.1-WJF8OKKmrpNZ65MR1S98K6nYzeHUXFH4B67.4gNLIr89fMfNzRZn.dapnXyk2Yw2) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Automated Gland MRI Radiomics for Predicting Time to Pathologic Progression during Prostate Cancer Active Surveillance [ View ORCID Profile](http://orcid.org/0000-0001-8962-559X)Hongye Zeng, Shreeram Athreya, Dingyuan Dai, Mara Pleasure, Vedrana Ivezic, Steve Raman, Leonard Marks, William Speier, Corey Arnold doi: https://doi.org/10.64898/2026.11.17.26368266 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Hongye Zeng 1 Department of Radiological Sciences, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hongye%2BZeng%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zeng%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHongye%2BZeng%2B) * [ORCID record for Hongye Zeng](http://orcid.org/0000-0001-8962-559X "Open in new tab") Shreeram Athreya 2 Department of Electrical & Computer Engineering, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shreeram%2BAthreya%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Athreya%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShreeram%2BAthreya%2B) Dingyuan Dai 2 Department of Electrical & Computer Engineering, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dingyuan%2BDai%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dai%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADingyuan%2BDai%2B) Mara Pleasure 3 Medical Informatics Home Area, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mara%2BPleasure%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pleasure%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMara%2BPleasure%2B) Vedrana Ivezic 3 Medical Informatics Home Area, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vedrana%2BIvezic%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ivezic%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVedrana%2BIvezic%2B) Steve Raman 1 Department of Radiological Sciences, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Steve%2BRaman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Raman%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASteve%2BRaman%2B) Leonard Marks 4 Department of Urology, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Leonard%2BMarks%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marks%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALeonard%2BMarks%2B) William Speier 5 Department of Bioengineering, University of California, Los Angeles * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=William%2BSpeier%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Speier%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilliam%2BSpeier%2B) Corey Arnold 1 Department of Radiological Sciences, University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Corey%2BArnold%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Arnold%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACorey%2BArnold%2B) * For correspondence: cwarnold@ucla.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1349314/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1349314/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1349314/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1349314/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1349314/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Repeated biopsies burden patients during prostate cancer active surveillance (AS). Existing MRI risk stratification tools avoiding biopsy remain limited by the difficulty of automated lesion segmentation. Purpose: To develop a model integrating gland MRI radiomics and clinicopathologic variables for predicting time to pathologic progression during prostate cancer AS. Materials and Methods: This retrospective single-institution study included men with grade group 1 or favorable grade group 2 prostate cancer undergoing AS with fusion-targeted and systematic biopsy (2010-2025). Gland segmentation used nnU-Net; gland radiomic features were selected by LASSO-penalized survival regression to train an XGBoost accelerated failure time model. Comparator models were assessed by C-index, time-dependent area under the receiver operating characteristic curve (AUC), Kaplan-Meier, and decision curve analysis. Results: Of 522 men (median age, 64 years [IQR, 59-68]), 410 were assigned by site to development and 112 to internal testing. Gland segmentation Dice was 0.89 +/- 0.04. The C-index was higher for the gland radiomics model (0.77) than for clinicopathologic (0.68) and lesion radiomics (0.68) models (adjusted P ≤ .017), with the highest time-dependent AUC at 36 months (0.87 [95% CI: 0.78, 0.94]). Progression-free survival was lower in high-risk than low-risk groups (36 months, 63.9% vs 100%; 48 months, 55.4% vs 93.8%; log-rank P The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.17.26368348v1 "Simulation and temporal validation of ICU trajectories after stroke: patient condition, transfer readiness and actual ICU exit")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1 "Promoter methylation of LDLR is not a common cause of familial hypercholesterolemia") Posted November 19, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/19/2026.11.17.26368266.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/19/2026.11.17.26368266.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Automated Gland MRI Radiomics for Predicting Time to Pathologic Progression during Prostate Cancer Active Surveillance Hongye Zeng, Shreeram Athreya, Dingyuan Dai, Mara Pleasure, Vedrana Ivezic, Steve Raman, Leonard Marks, William Speier, Corey Arnold medRxiv 2026.11.17.26368266; doi: https://doi.org/10.64898/2026.11.17.26368266 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368266v1%26text%3DAutomated%2520Gland%2520MRI%2520Radiomics%2520for%2520Predicting%2520Time%2520to%2520Pathologic%2520Progression%2520during%2520Prostate%2520Cancer%2520Active%2520Surveillance "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368266v1%26t%3DAutomated%2520Gland%2520MRI%2520Radiomics%2520for%2520Predicting%2520Time%2520to%2520Pathologic%2520Progression%2520during%2520Prostate%2520Cancer%2520Active%2520Surveillance "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368266v1%26title%3DAutomated%2520Gland%2520MRI%2520Radiomics%2520for%2520Predicting%2520Time%2520to%2520Pathologic%2520Progression%2520during%2520Prostate%2520Cancer%2520Active%2520Surveillance%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368266v1%26title%3DAutomated%2520Gland%2520MRI%2520Radiomics%2520for%2520Predicting%2520Time%2520to%2520Pathologic%2520Progression%2520during%2520Prostate%2520Cancer%2520Active%2520Surveillance "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.17.26368266) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.17.26368266v1&count=horizontal&via=&text=Automated%20Gland%20MRI%20Radiomics%20for%20Predicting%20Time%20to%20Pathologic%20Progression%20during%20Prostate%20Cancer%20Active%20Surveillance&counturl=www.medrxiv.org/content/10.64898/2026.11.17.26368266v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (642) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (927) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (355) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5055) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (432) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (681) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1703) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16339) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (37) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1248) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7328) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (759) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1101) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5346) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1480) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1847) * [Hematology](https://www.medrxiv.org/collection/hematology) (604) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1389) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16534) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1209) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (702) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (757) * [Neurology](https://www.medrxiv.org/collection/neurology) (7659) * [Nursing](https://www.medrxiv.org/collection/nursing) (380) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1142) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1306) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1045) * [Oncology](https://www.medrxiv.org/collection/oncology) (3765) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1105) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (413) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (473) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (506) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (144) * [Pathology](https://www.medrxiv.org/collection/pathology) (726) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1877) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (758) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (791) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6184) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (10047) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2559) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/reha
## Related Clinical Research

- [American Cancer Society now recommends biennial PSA screening for men 50–69](https://medichelpline.com/clinical-feed/stat-news-0-experts-update-prostate-cancer-screening-guidelines-for-men.md)
- [ACS updates prostate cancer guidance: routine biennial PSA screening for men 50–69](https://medichelpline.com/clinical-feed/stat-news-1-american-cancer-society-revises-guidelines-urges-routine-psa-screening-for.md)
- [Machine learning prediction of prostate cancer and clinically significant disease at biopsy in an](https://medichelpline.com/clinical-feed/medrxiv-3-machine-learning-models-for-predicting-prostate-cancer-and-clinically.md)
- [Simulated ICU Trajectories After Stroke: Temporal Validation Using MIMIC‑IV](https://medichelpline.com/clinical-feed/medrxiv-1-simulation-and-temporal-validation-of-icu-trajectories-after-stroke-patient.md)
- [EHR Phenotype Choice Alters Outcomes: Three Invasive Breast Cancer Definitions Compared in TriNetX](https://medichelpline.com/clinical-feed/plos-one-6-electronic-health-record-phenotype-choice-and-real-world-outcome-estimates-a.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.